Summary of Study ST000978
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000668. The data can be accessed directly via it's Project DOI: 10.21228/M8B69G This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST000978 |
Study Title | Metabolomics biomarkers and the risk of overall mortality and ESRD in CKD: results from the Progredir Cohort. |
Study Type | ongoing cohort study |
Study Summary | 454 CKD participants were originally recruited from the outpatient services from Hospital das Clinicas, Sao Paulo. Extensive baseline data and biobank were collected between 2012-2013 in the Clinical Research Center, Universitary Hospital, Sao Paulo. Participants are being actively followed for events of mortality, renal replacement therapy and CVD. Death certificates are obtained from State and National Registries. For the this uploaded data, events were determined up to May 2017 (median follow-up time of 3 y). Censoring data was considered as the last day of contact. |
Institute | University of Sao Paulo |
Department | Clinical Research Center, Universitary Hospital, Sao Paulo University |
Laboratory | Laboratory of Genetics and Molecular Cardiology, Heart Institute |
Last Name | Titan |
First Name | Silvia |
Address | 255 Av Dr Eneas Carvalho Aguiar, Cerqueira César, Sao Paulo, Sp, Brazil, 05403-000 |
smotitan@gmail.com | |
Phone | +1-413-362-4377 |
Submit Date | 2018-05-22 |
Total Subjects | 451 |
Study Comments | Events are overall mortality, RRT, and a composite outcome of mortality and RRT. In addition, we also provided the variable for competitive data analysis (RRT considering the competing effect of death). Please see below for description of Study Design. Cox_mortality: death events (for Cox proportional hazard models) Cox_RRT: renal replacement therapy events (for Cox proportional hazard models) Cox_composite_deathRRT: death events AND renal replacement therapy events (for Cox proportional hazard models) Competitive_RRTvs death: death or renal replacement therapy events (for competitive risk analysis) Time_death: follow-up time for death events and censored-participants (for Cox models) Time_Cox_RRT: follow-up time for renal replacement therapy events and censored-participants (for Cox models) Time_composite_deathRRT: follow-up time for death AND renal replacement therapy and censored-participants (for Cox models) Time_competitive_TRSvsDeath: follow-up time for renal replacement therapy, death or censored-participants (for competitive analysis) |
Analysis Type Detail | GC-MS |
Release Date | 2018-07-17 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR000668 |
Project DOI: | doi: 10.21228/M8B69G |
Project Title: | Metabolomics biomarkers and the risk of overall mortality and ESRD in CKD: results from the Progredir Cohort. |
Project Type: | Cohort Study |
Project Summary: | Prospective analysis on events of mortality, renal-replacement therapy and a composite outcome of both in a CKD cohort study evaluating metabolomics (untargeted GC-MS) biomakers. |
Institute: | University of Sao Paulo |
Department: | Clinical Research Center, Universitary Hospital, Sao Paulo University |
Laboratory: | Laboratory of Genetics and Molecular Cardiology, Heart Institute |
Last Name: | Titan |
First Name: | Silvia |
Address: | 255 Av Dr Eneas Carvalho Aguiar, Cerqueira César, Sao Paulo, Sp, Brazil, 05403-000 |
Email: | smotitan@gmail.com |
Phone: | +1-413-362-4377 |
Funding Source: | FAPESP; CNPq, Brazilian Ministry of Health (Science and Technology Department); FINEP. |
Subject:
Subject ID: | SU001017 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Age Or Age Range: | >30 |
Gender: | Male and female |
Human Inclusion Criteria: | Patients from the Hospital das Clínicas Outpatient Clinics ≥30 years-old and with at least two measurements of creatinine (with a minimum interval of 3 months) ≥1.6 mg/dL for men and ≥1.4 mg/dL for women were considered potential candidates. |
Human Exclusion Criteria: | Patients attending oncology, psychiatry, urology, HIV/AIDS, viral hepatitis and glomerulonephritis services were excluded. The remaining candidates were then contacted by phone and invited to participate if no exclusion criteria were met (hospitalization or acute myocardial infarction in the last 6 months, autoimmune diseases, pregnancy, psychiatric diseases, ongoing chemo or immunosuppressive therapy, ongoing renal replacement therapy, glomerulonephritis, HIV/AIDS infection, hepatitis C and B, and any previous organ transplantation). |
Species Group: | Mammals |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | Cox_Mortality | Cox_RRT | Cox_Composite_DeathRRT | Competitive_RRTvsDeath |
---|---|---|---|---|---|
SA059449 | 279 | . | . | . | . |
SA059450 | 141 | N | . | . | . |
SA059451 | 242 | N | . | . | . |
SA059452 | 47 | N | . | . | . |
SA059453 | 296 | N | . | . | . |
SA059454 | 357 | N | . | . | . |
SA059455 | 280 | N | N | N | N |
SA059456 | 281 | N | N | N | N |
SA059457 | 283 | N | N | N | N |
SA059458 | 286 | N | N | N | N |
SA059459 | 285 | N | N | N | N |
SA059460 | 284 | N | N | N | N |
SA059461 | 282 | N | N | N | N |
SA059462 | 276 | N | N | N | N |
SA059463 | 271 | N | N | N | N |
SA059464 | 268 | N | N | N | N |
SA059465 | 267 | N | N | N | N |
SA059466 | 265 | N | N | N | N |
SA059467 | 272 | N | N | N | N |
SA059468 | 273 | N | N | N | N |
SA059469 | 277 | N | N | N | N |
SA059470 | 287 | N | N | N | N |
SA059471 | 275 | N | N | N | N |
SA059472 | 274 | N | N | N | N |
SA059473 | 278 | N | N | N | N |
SA059474 | 289 | N | N | N | N |
SA059475 | 309 | N | N | N | N |
SA059476 | 308 | N | N | N | N |
SA059477 | 307 | N | N | N | N |
SA059478 | 306 | N | N | N | N |
SA059479 | 310 | N | N | N | N |
SA059480 | 312 | N | N | N | N |
SA059481 | 317 | N | N | N | N |
SA059482 | 316 | N | N | N | N |
SA059483 | 315 | N | N | N | N |
SA059484 | 314 | N | N | N | N |
SA059485 | 305 | N | N | N | N |
SA059486 | 304 | N | N | N | N |
SA059487 | 293 | N | N | N | N |
SA059488 | 292 | N | N | N | N |
SA059489 | 291 | N | N | N | N |
SA059490 | 263 | N | N | N | N |
SA059491 | 294 | N | N | N | N |
SA059492 | 295 | N | N | N | N |
SA059493 | 303 | N | N | N | N |
SA059494 | 302 | N | N | N | N |
SA059495 | 298 | N | N | N | N |
SA059496 | 297 | N | N | N | N |
SA059497 | 288 | N | N | N | N |
SA059498 | 261 | N | N | N | N |
SA059499 | 223 | N | N | N | N |
SA059500 | 222 | N | N | N | N |
SA059501 | 219 | N | N | N | N |
SA059502 | 218 | N | N | N | N |
SA059503 | 224 | N | N | N | N |
SA059504 | 225 | N | N | N | N |
SA059505 | 231 | N | N | N | N |
SA059506 | 229 | N | N | N | N |
SA059507 | 1 | N | N | N | N |
SA059508 | 227 | N | N | N | N |
SA059509 | 217 | N | N | N | N |
SA059510 | 216 | N | N | N | N |
SA059511 | 200 | N | N | N | N |
SA059512 | 199 | N | N | N | N |
SA059513 | 197 | N | N | N | N |
SA059514 | 196 | N | N | N | N |
SA059515 | 203 | N | N | N | N |
SA059516 | 205 | N | N | N | N |
SA059517 | 212 | N | N | N | N |
SA059518 | 211 | N | N | N | N |
SA059519 | 210 | N | N | N | N |
SA059520 | 206 | N | N | N | N |
SA059521 | 232 | N | N | N | N |
SA059522 | 233 | N | N | N | N |
SA059523 | 254 | N | N | N | N |
SA059524 | 251 | N | N | N | N |
SA059525 | 250 | N | N | N | N |
SA059526 | 249 | N | N | N | N |
SA059527 | 255 | N | N | N | N |
SA059528 | 256 | N | N | N | N |
SA059529 | 319 | N | N | N | N |
SA059530 | 260 | N | N | N | N |
SA059531 | 259 | N | N | N | N |
SA059532 | 258 | N | N | N | N |
SA059533 | 248 | N | N | N | N |
SA059534 | 247 | N | N | N | N |
SA059535 | 240 | N | N | N | N |
SA059536 | 237 | N | N | N | N |
SA059537 | 236 | N | N | N | N |
SA059538 | 235 | N | N | N | N |
SA059539 | 241 | N | N | N | N |
SA059540 | 243 | N | N | N | N |
SA059541 | 246 | N | N | N | N |
SA059542 | 245 | N | N | N | N |
SA059543 | 244 | N | N | N | N |
SA059544 | 262 | N | N | N | N |
SA059545 | 321 | N | N | N | N |
SA059546 | 399 | N | N | N | N |
SA059547 | 398 | N | N | N | N |
SA059548 | 397 | N | N | N | N |
Collection:
Collection ID: | CO001011 |
Collection Summary: | Storage conditions: Liquid nitrogen, Time of collection: Morning fasting. |
Sample Type: | Blood (serum) |
Collection Method: | Morning - fasting |
Volumeoramount Collected: | 0.5 ml |
Storage Conditions: | Described in summary |
Collection Vials: | Straws |
Collection Tube Temp: | Room temperature |
Treatment:
Treatment ID: | TR001031 |
Treatment Summary: | None |
Sample Preparation:
Sampleprep ID: | SP001024 |
Sampleprep Summary: | 70uL os serum was thawed on ice and added 300uL of acetronile, isopropanol and water solution (3:3:2 v/v) followed by spike of 5uL of d27 myristic acid (3mg/ml) as internal standard. Samples were vortexed and centrifuged to 15800xg during 15 minutes at 4C. 320uL of supernatante were transferred to a new tube and dried in speedvac during 18 hours. Residues were suspended in 50µL methoxyamine in pyridine solution (40mg/mL), 3µL of FAME (Fatty acid methyl ester ) was added, and the mixture was vortexed for 3 min. This methoximation reaction was performed at room temperature for 16h, followed by trimethylsilylation for 1h adding 100µL MSTFA (N-methyl-N-trimethylsilyltrifluoroacetamine) with 1% TMCS (trimethylchlorosilane) (Sigma-Aldrich). After derivatization, 1µL of this derivative was used for Gas Chromatography Mass Spectrometry (GC/MS) analysis. Storage condition: Desiccator at 4 degree |
Processing Method: | Protein Precipitation followed by metabolite extraction |
Processing Storage Conditions: | On ice |
Extraction Method: | Acetonitrile:Isopropanol: water(3:3:2 v/v) |
Extract Storage: | Described in summary |
Sample Resuspension: | Methoxyamine in pyridine |
Sample Derivatization: | MSTFA + 1% TMCS |
Sample Spiking: | 5uL of d27 Myristic Acid (3mg/mL) and FAME |
Combined analysis:
Analysis ID | AN001602 |
---|---|
Analysis type | MS |
Chromatography type | GC |
Chromatography system | Agilent 7890B |
Column | DB5-MS + 10m Duraguard capillary (Agilent 122-5532G) |
MS Type | EI |
MS instrument type | Single quadrupole |
MS instrument name | Agilent 5975C |
Ion Mode | POSITIVE |
Units | peak height |
Chromatography:
Chromatography ID: | CH001124 |
Instrument Name: | Agilent 7890B |
Column Name: | DB5-MS + 10m Duraguard capillary (Agilent 122-5532G) |
Column Temperature: | 60°C for 1 min, and then increased to 310°C at a rate of 10°C/min |
Flow Rate: | 0.736ml/min |
Injection Temperature: | 250C |
Sample Injection: | 1uL |
Analytical Time: | 37 minutes |
Capillary Voltage: | 70eV |
Oven Temperature: | 60°C for 1 min, and then increased to 310°C at a rate of 10°C/min |
Weak Wash Solvent Name: | Methanol |
Weak Wash Volume: | 3x 5uL |
Strong Wash Solvent Name: | Isopropanol |
Strong Wash Volume: | 3x 5uL |
Sample Syringe Size: | 10uL |
Chromatography Type: | GC |
MS:
MS ID: | MS001480 |
Analysis ID: | AN001602 |
Instrument Name: | Agilent 5975C |
Instrument Type: | Single quadrupole |
MS Type: | EI |
Ion Mode: | POSITIVE |
Helium Flow: | 0.736ml/min |
Ionization Energy: | 70ev |
Reagent Gas: | Helium |
Scan Range Moverz: | 50 to500m/z |